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A recent study of two widely used angiotensin receptor
blockers reported a reduced risk of cardiovascular
events ( 14.4%) when using candesartan compared
with losartan in the primary treatment of hypertension.
In addition to clinical benefits, costs associated with
treatment strategies must be considered when alloca-
ting scarce health-care resources. The aim of this study
was to assess resource use and costs of losartan and
candesartan in hypertensive patients. Resource use
(drugs, outpatient contacts, hospitalizations and labora-
tory tests) associated with losartan and candesartan
treatment was estimated in 14100 patients in a real-life
clinical setting. We electronically extracted patient data
from primary care records and mandatory Swedish
national registers for death and hospitalization. Patients
treated with losartan had more outpatient contacts
(þ15.6%), laboratory tests (þ13.8%) and hospitaliza-
tions (þ13.8%) compared with the candesartan group.
During a maximum observation time of 9 years, the
mean total costs per patient were 10369 Swedish kronor
(95% confidence interval: 3109–17629) higher in the
losartan group. In conclusion, prescribing candesartan
for the primary treatment of hypertension results in lower
long-term health-care costs compared with losartan.
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Introduction
The prevalence of hypertension is approximately
40% in Europe,
1 and it is estimated that the risk of
becoming hypertensive during a lifetime exceeds
90%.
2 Hypertension is one of the most important
risk factors in the development of cardiovascular
disease and blood pressure lowering treatment is
essential to improve patient health and limit the
burden on the health-care system. Although it has
been shown that the angiotensin receptor blockers
losartan
3,4 and candesartan
5,6 are effective antihyper-
tensives, they have only recently been compared
in a real-life clinical situation for the primary
treatment of hypertension.
7 The study showed that
candesartan lowered the risk of cardiovascular
events compared with losartan (hazard ratio: 0.86,
95% confidence interval, CI: 0.77–0.96) during a
median follow-up of 2.0 years.
7 Although this study
showed that prescribing candesartan is associated
with fewer clinical events compared with losartan,
health-care decision makers also need to consider
the costs associated with different treatment strate-
gies to determine value for money when prioritizing
scarce health-care resources.
8 When evaluating the
economic consequences of different treatments in
this context it is not only the cost of the adminis-
tered drugs that is important, but also the costs
associated with the development of clinical condi-
tions requiring contacts with primary care and
hospitalizations.
9
In this study, data on resource use associated with
losartan and candesartan in a real-life clinical
setting were electronically extracted from primary
care records and mandatory Swedish national
registers for death and hospitalization. Using data
on hospitalizations, use of study drugs and contacts
with primary health care, the objective of this study
was to estimate and compare resource use and costs
of losartan vs candesartan in adult patients who
were originally prescribed candesartan or losartan
for hypertension from 1999 to 2007.
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The design of the study, including the process of
extracting data from primary care records and
registers, has been described in detail elsewhere.
7
In brief, patients with no cardiovascular disease
except hypertension and/or type II diabetes were
included in the study if losartan or candesartan were
prescribed during the years 1999–2007. Patients
were followed up until death, no further prescrip-
tions of initial angiotensin receptor blocker, switch
to another angiotensin receptor blocker or end of
study period (31 December 2007).
Hospitalizations before index prescription
As reported earlier, there were small differences in
baseline characteristics between the treatment
groups, although the losartan group had a higher
prevalence of diabetes (þ2.8%), were less fre-
quently treated with thiazides ( 2.3%) and b-
blockers ( 2.0%), and more frequently treated with
glucose lowering drugs (þ1.7%), statins (þ1.3%)
and antithrombotics (þ0.8%) compared with the
candesartan group.
7 Further analyses were under-
taken in this study to ensure that the treatment
groups were similar at baseline. All hospital admis-
sions for non-cardiovascular causes before the index
prescription were assessed with data from the
National Discharge Registry, covering every hospital
admission for any reason in Sweden from year 1984.
It should be noted that hospitalizations for cardio-
vascular causes were excluded in this analysis by
design.
Resource use
The use of study drugs, outpatient contacts and
laboratory tests were extracted from the electronic
primary care records.
7 The total number of days and
doses of candesartan or losartan prescription were
recorded. Outpatient contacts were categorized into
actual visits to the primary care centre or telephone
calls. Furthermore, contacts were categorized into
physician, nurse or other (for example a phy-
siotherapist). A number of different sets of labora-
tory tests were recorded (listed in Table 1).
Hospitalizations, procedures and diagnosis-related
groups (DRG) codes were extracted from the Na-
tional Discharge Registry by the National Board of
Health and Welfare in Sweden.
10,11
Unit costs
All unit costs applied in the study are presented in
Table 1. The prices of study drugs were Merck Sharp
& Dome (losartan) and AstraZeneca (candesartan)
manufactured versions.
12 The lowest price per pill
for all pack sizes was used to determine the daily
cost for each drug and dose. Unit costs applied
for outpatient visits were based on the South
East County Council region in Sweden.
13 Costs for
laboratory tests were based on prices from the
Centre for Laboratory Medicine in O ¨ stergo ¨tland,
Sweden.
14 Unit costs for hospitalizations were
determined from the DRG codes using the most
recent Nord-DRG.
15 Although these costs are from
2007, we did not inflate them to 2008/2009 prices.
More than 6000 inpatient visits with 400 different
DRG codes were identified in the study. Most
common DRG codes were chest pain/angina pectoris
(DRGs 140 and 143; 5% of total hospitalizations),
hospitalization with PCI procedure (DRGs 112A–
112D; 3% of all hospitalizations), arrhythmias
(DRGs 138 and 139; 3% of all hospitalizations) and
myocardial infarctions (DRG codes 121–123; 2.5%
of all hospitalizations). Each hospitalization was,
therefore, associated with an ICD code that was
used to determine clinical outcome and a DRG code
that was used for costing. The same primary ICD
diagnosis could, therefore, result in different DRG
codes (and thus different costs) because of secondary
Table 1 Unit costs applied in the analysis
Cost item Unit cost (SEK)
Study drugs Per day
Candesartan 4mg 5.9
Candesartan 8mg 5.4
Candesartan 16mg 7.1
Candesartan 16mg/12.5mg 7.1
Losartan 50mg 6.0
Losartan 100mg 9.9
Losartan 50mg/12.5mg 7.0
Losartan 100mg/25mg 10.9
Outpatient contacts Per contact
Physician visit 1715
Physician phone contact 572
Nurse visit 570
Nurse phone contact 190
Other visit 570
Other phone contact 190
Laboratory tests Per test
Total serum cholesterol 11
HDL and LDL cholesterol 32
Triglycerides 11
Blood glucose 27
HbA1C 74
Creatinine 11
Micro-albumine 37
Potassium 11
Hospitalisations Per event
a
Heart failure 33919
Cardiac arrhythmias 29146
Peripheral artery disease
b 63260
Chronic ischaemic heart disease 34079
Myocardial infarction 47748
Stroke
c 43830
Unstable angina 42001
Elective coronary revascularization 41387
Abbreviations: DRG, diagnosis-related groups; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; SEK, Swedish kronor.
aMean cost per ICD-coded cardiovascular event according to DRG.
bIncludes aortic aneurysms.
cIschaemic, haemorrhagic stroke and transient ischaemic attacks.
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the same primary ICD diagnosis may lead to
hospitalizations with different length of stay and
different procedures. In Table 1, the mean DRG costs
associated with hospitalizations for cardiovascular
causes according to primary ICD diagnoses are
presented.
Statistical analysis
To analyse total costs, unit costs were multiplied by
the observed resource use, which provided a total
cost per patient. Mean costs for candesartan and
losartan were then calculated and compared using
data on all patients in the study. A large proportion
of patients were subjected to administrative censor-
ing at the end of follow-up (31 December 2007). To
account for this, it has been proposed to weight the
costs in different time intervals by the inverse of the
probability of being observed in an interval.
16,17 In
this study, the first interval was 0–6 months with
annual intervals thereafter. The accumulated total
health-care costs over time are presented together
with the number of patients contributing with data
in each interval. Given the relatively large sample
size, t-tests and standard OLS regression were
performed to test for statistical significance.
18 Re-
sampling bootstrap techniques were used to check
the robustness of the parametric t-test, as the
observed cost data was substantially skewed.
17,18
Costs were discounted by 3% and are based on a
Swedish health-care setting and are presented in
2008/2009 Swedish kronor (SEK); 10 SEK is
approximately 1 Euro or 1.40 US dollars in February
2010.
As the patent of branded losartan (Cozaar) will
soon expire in many countries, we performed
separate analyses to account for the expected
decrease in costs of generic losartan compared with
branded Cozaar. Although it is difficult to precisely
predict the magnitude of this price reduction,
previous experience from Sweden suggests that a
70–90% reduction is a likely scenario. Therefore,
analyses of 70, 80 and 90% reductions of the
branded Cozaar price were applied. More patients
on losartan were diabetic at inclusion in the study.
To assess whether this had any impact on the
results, a separate analysis was performed excluding
patients with diabetes at baseline.
All statistical analyses were performed using Stata
version 8 (Stata Statistical Software: Release 8, Stata
Corporation, College Station, TX, USA).
Results
Hospitalizations before index prescription
The number of patients hospitalized for any reason
excluding cardiovascular disease before index pre-
scription were similar in both groups; 3286 (48.5%)
in the losartan group and 3560 (48.6%) in the cande-
sartan group. Furthermore, no differences in the
mean number of days in hospital before the index
prescription were observed; 5.9 days per patient in
both the losartan and the candesartan group.
Resource use
The observed resource use is presented in Table 2.
Patients treated with losartan had on an average 3.5
(95% CI: 2.4–4.6) more outpatient contacts and 1.6
(95% CI: 1.12–2.17) more laboratory tests compared
with candesartan patients. The losartan group had
slightly more hospitalizations (mean difference:
0.06, 95% CI: 0.01–0.10) resulting in 0.40 (95% CI:
0.01–0.80) more mean number of days in hospital for
the losartan group. There was no difference between
the treatment groups in the mean number of days on
study medication.
Table 2 Mean number of resource use by treatment group
Losartan (n¼6771) Candesartan (n¼7329) Difference (95% confidence interval)
Study drugs
Days with prescription (s.e.) 1220.9 (11.4) 1221.3 (11.2)  0.4 ( 31.8–31.0)
Outpatient contacts
Physician visits (s.e.) 10.9 (0.17) 9.5 (0.14) –
Physician phone contacts (s.e.) 3.3 (0.06) 3.1 (0.06) –
Nurse visits (s.e.) 7.8 (0.23) 6.4 (0.2) –
Nurse phone contacts (s.e.) 3.0 (0.08) 2.6 (0.07) –
Other visits (s.e.) 1.0 (0.06) 0.8 (0.06) –
Other phone contacts (s.e.) 0.07 (0.01) 0.09 (0.01) –
Any visit (s.e.) 26.0 (0.43) 22.5 (0.38) 3.5 (2.4–4.6)
Laboratory tests
Any laboratory tests (s.e.) 13.3 (0.19) 11.6 (0.18) 1.6 (1.1–2.2)
Hospitalizations
Number of hospitalizations (s.e.) 0.5 (0.02) 0.4 (0.01) 0.06 (0.01–0.10)
Abbreviation: s.e., standard error.
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The estimated discounted mean health-care costs
per patient by treatment group are presented in
Table 3. The cost of study drugs was SEK 790 higher
for losartan compared with candesartan. Costs for
laboratory tests were small compared with total
costs and did not differ between the two treatment
groups. The increased number of outpatient contacts
for the losartan group resulted in SEK 3463 higher
costs compared with candesartan. Costs associated
with hospitalization resulted in SEK 6101 higher
costs with losartan compared with candesartan. Of
the difference in costs for hospitalizations, SEK
2675 (95% CI: 861–4489) were due to hospitaliza-
tions with ICD diagnoses defined as cardiovascular,
and SEK 3426 (95% CI:  1931–8786) were due to
hospitalizations with ICD codes not primarily
defined as cardiovascular. The mean total health-
care costs with losartan were SEK 10369 (95% CI:
3109–17629) higher than that of candesartan over a
follow-up of maximum 9 years. The bootstrap
analysis showed similar results to the parametric
analysis (mean difference SEK: 10240, 95% CI:
3912–19222). When controlling for diabetes, age
and gender, the difference in total health-care costs
was SEK 9280 (95% CI: 2024–16535). The mean
total costs per patient over time, by treatment group,
are presented in Figure 1.
Sensitivity analyses
The results of running different scenario analyses
assessing the effect of a price reduction of losartan
are presented in Figure 2. With a price reduction of
losartan of 70%, the mean total health-care cost of
losartan is still numerically higher compared with
candesartan, but this was not significant. A price
reduction of 80 or 90% results in lower mean total
health-care cost of losartan compared with candesartan,
although these differences were also not statistically
significant. Patients with diabetes had higher costs
regardless of treatment group. Excluding patients with
diabetes at baseline, the mean total costs with losartan
was SEK 9332 (95% CI: 1136–17529, P-value: 0.03)
higher compared with candesartan, based on 11773
patients (5556 with losartan and 6217 with cande-
sartan). Corresponding mean difference for patients
with diabetes at baseline was 11855 (95% CI:  2854–
26564, P-value: 0.11), based on 2327 patients (1215
with losartan and 1112 with candesartan).
Table 3 Mean total discounted health-care costs by treatment group
Losartan (n¼6771) Candesartan (n¼7329) Difference (95% confidence interval) P-value
Study drugs 13211 12422 790 (209–1370) 0.008
Outpatients contacts 43365 39902 3463 (874–6051) 0.009
Laboratory tests 659 644 15 ( 28–58) 0.500
Hospitalizations 33080 26979 6101 (255–11 950) 0.041
Total 90316 79947 10369 (3 109–17 629) 0.005
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Figure 1 Mean total discounted health-care costs over time by treatment group. Numbers show the difference in mean total health-care
costs (losartan compared with candesartan) with 95% CIs in brackets. SEK¼Swedish kronor.
A follow-up of 14100 patients
M Henriksson et al
133
Journal of Human HypertensionDiscussion
This study has shown that prescribing candesartan
for the primary treatment of hypertension is asso-
ciated with a reduced use of health-care resources in
the long term compared with losartan. At current
prices of losartan, this reduction in health-care
resources translated into a reduction in total mean
health-care costs of SEK 10369 per patient pre-
scribed candesartan compared with losartan over a
follow-up of 9 years. Owing to patent expiry of
branded losartan (Cozaar) in many countries in the
near future, the impact of a reduced price of losartan
for the results of the present study was investigated.
Clearly, with a large reduction in the price of
losartan, the total drug costs of candesartan will be
higher compared with losartan. A price reduction of
losartan of 80% or more of the current price will
lead to numerically higher total health-care costs for
candesartan compared with losartan. However, the
difference in mean total health-care costs was not
statistically significant with a 90% reduction in the
price of losartan. These results should be interpreted
in the light of the observed 14.4% reduction in
cardiovascular events with candesartan compared
with losartan.
7 At current prices of losartan, pre-
scribing candesartan will reduce total health-care
cost and improve health outcomes, indicating that
candesartan should be preferred to losartan from a
clinical and a health-policy perspective. With a large
reduction of the price of generic losartan, total
health-care costs may be numerically higher with
candesartan compared with losartan. In such a
scenario, a more formal evaluation of cost-effective-
ness may be warranted. Such an analysis should
consider health-related quality of life and long-term
survival prognosis of patients with and without
cardiovascular events.
It should be noted that we did not include the
costs of other drugs in this study. The use of most
other drugs was similar between the treatment
groups, with the exception of a more frequent use
of thiazides in the losartan group.
7 The inclusion of
other drugs in our analyses could, therefore, have
slightly strengthened the findings of this study.
The design of this study has strengths and
weaknesses of which most have been discussed in
a recent publication.
7 One of the strengths with the
methods used in this study is that resource use data
was collected from a real-life clinical setting by
extracting data from patient records and mandatory
nationwide registers. This reduces the risk of
protocol-driven costs and implies that it should be
possible to extrapolate the results to clinical prac-
tice. Furthermore, it should be emphasized that this
methodology enabled a comparison of health-care
resource use and costs between candesartan and
losartan using 436000 patient years of follow-up.
Such an analysis is highly unlikely to have been
initiated prospectively. A possible limitation of this
study is that selection bias can never be eliminated
entirely in a retrospective study. However, the
method enabled us to extract detailed clinical
baseline data and patient history. In the recent
publication reporting on cardiovascular end points
on the same patient material, it was shown that the
differences of cardiovascular risk were robust
despite several adjustment methods for baseline
differences.
7 In the current analysis, we have
additionally assessed any hospitalizations before
the index prescription without disclosing any
differences between the treatment groups. When
considering hospitalizations before the index pre-
scription as an expression of baseline disease
burden (co-morbidity), this strongly suggests that
the groups are comparable at baseline. The results
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controlling for the same covariates as in the clinical
study. It should also be pointed out that the results
are based on a Swedish patient material, and thus
reflect a Swedish health-care system. Extrapolating
the results to other health-care systems should
always be accompanied by a careful assessment
whether a Swedish health-care setting can plausibly
be assumed representative.
Conclusions
The study shows that the use of candesartan for the
primary treatment of hypertension results in lower
mean total health-care costs compared with losar-
tan. Although an expected reduction in the cost of
losartan because of patent expiry will lead to lower
drug costs for losartan compared with candesartan,
the total costs for the health-care system are expected
to be similar for the two treatment strategies as cande-
sartan is associated with a reduction in costly clinical
events.
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